Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021

(2022) Fabio Efficace et al.   Clinical Lymphoma Myeloma & Leukemia

Health impacts of the Russian invasion in Ukraine: need for global health action

(2022) Olha Zaliska et al.   LANCET

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

(2022) Maria-Victoria Mateos et al.   LEUKEMIA

Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells

(2022) Pritha Agarwalla et al.   NATURE BIOTECHNOLOGY

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition

(2022) Bob T. Li et al.   NATURE MEDICINE

Cancer treatments should benefit patients: a common-sense revolution in oncology

(2022) Bishal Gyawali et al.   NATURE MEDICINE

Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers

(2022) Wai Hoong Chang et al.   NATURE MEDICINE

Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma

(2022) Alice J. Chen et al.   VALUE IN HEALTH

Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study

(2022) Christopher Staffi Buradagunta et al.   Blood Cancer Journal

Financial toxicity in hematological malignancies: a systematic review

(2022) Evguenia Ouchveridze et al.   Blood Cancer Journal

Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training

(2022) Claire Horgan et al.   Lancet Haematology

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

(2022) Gita Thanarajasingam et al.   Lancet Haematology

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms

(2022) Samer Al Hadidi et al.   JAMA Network Open

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2021) M.A. Dimopoulos et al.   ANNALS OF ONCOLOGY

Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation

(2021) Ching Lam et al.   CYTOTHERAPY

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

(2021) Philippe Moreau et al.   LANCET ONCOLOGY

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

(2021) Evangelos Terpos et al.   Blood Cancer Journal

Evaluating eligibility criteria of oncology trials using real-world data and AI

(2021) Ruishan Liu et al.   NATURE

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

(2021) Joseph C. Del Paggio et al.   JAMA Oncology

The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma

(2021) Shwetha H Manjunath et al.   CLINICAL CANCER RESEARCH

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

(2021) Stephen J Schuster et al.   LANCET ONCOLOGY

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland

(2021) Maria Kamusheva et al.   Frontiers in Public Health

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

(2021) Sham Mailankody et al.   BLOOD

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

(2021) Michael Maschan et al.   Nature Communications

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

(2021) P.J. Hayden et al.   ANNALS OF ONCOLOGY

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus

(2020) Jakob R. Passweg et al.   BONE MARROW TRANSPLANTATION

Evaluating Treatment Tolerability in Cancer Clinical Trials using the Toxicity Index

(2020) Gillian Gresham et al.   JNCI-Journal of the National Cancer Institute

Real-world evidence and regulatory drug approval

(2020) Michael J. Raphael et al.   Nature Reviews Clinical Oncology

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

(2020) S. Depil et al.   NATURE REVIEWS DRUG DISCOVERY

Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment

(2020) Heinz Ludwig et al.   ONCOLOGIST

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges

(2020) Binod Dhakal et al.   BONE MARROW TRANSPLANTATION

Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma

(2020) Ajeet Gajra et al.   Immunotherapy

Development of CAR-T cell therapies for multiple myeloma

(2020) Nico Gagelmann et al.   LEUKEMIA

Disease and healthcare burden of COVID-19 in the United States

(2020) Ian F. Miller et al.   NATURE MEDICINE

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

(2020) Valentín Ortíz-Maldonado et al.   MOLECULAR THERAPY

Persistent Challenges with Treating Multiple Myeloma Early

(2020) Aaron Michael Goodman et al.   BLOOD

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods

(2019) Richard P. Harrison et al.   CYTOTHERAPY

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma

(2019) John K. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Conceptual Model for Accrual to Cancer Clinical Trials

(2019) Simon J. Craddock Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

(2019) John A. Snowden et al.   BONE MARROW TRANSPLANTATION

In vivo generated human CAR T cells eradicate tumor cells

(2019) Shiwani Agarwal et al.   OncoImmunology

B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis

(2019) Nico Gagelmann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities

(2018) Rajshekhar Chakraborty et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

(2017) Tyrel T. Smith et al.   Nature Nanotechnology

Clinicians’ Expectations of the Benefits and Harms of Treatments, Screening, and Tests

(2017) Tammy C. Hoffmann et al.   JAMA Internal Medicine

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Costs of haematological disease high and rising

(2016) Tony Green et al.   Lancet Haematology

The Use of Superlatives in Cancer Research

(2016) Matthew V. Abola et al.   JAMA Oncology

Modernizing Eligibility Criteria for Molecularly Driven Trials

(2015) Edward S. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study

(2015) Scott F Huntington et al.   Lancet Haematology

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

(2015) Amylou C. Dueck et al.   JAMA Oncology

Health outcomes in economic evaluation: the QALY and utilities

(2010) S. J. Whitehead et al.   BRITISH MEDICAL BULLETIN

Socioeconomic Inequalities in Health in 22 European Countries

(2008) Johan P. Mackenbach et al.   NEW ENGLAND JOURNAL OF MEDICINE